UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-35814 Harrow, Inc. (Exact name of registrant as specified in its charter) Delaware 45-0567010 (State or othe ...

H A R R O W * Your patients. Our purpose. Poised to become a top-tier U.S. ophthalmic pharmaceutical company. o Service 4,000+ monthly accounts of over 10,000 prescribers and institutions. Management utilizes Adjusted EBITDA, an unaudited financial measure that is not calculated in accordance with GAAP, to evaluate the Company's financial results and performance and to plan and forecast future periods. Investors are encouraged to review the Company's complete results of operations and additional information ...

Harrow Health, Inc. (NASDAQ:HROW) Q2 2023 Earnings Conference Call August 9, 2023 4:45 PM ET Company Participants Jamie Webb - Director-Communications & Investor Relations Mark L. Baum - Chief Executive Officer & Chairman-Board of Directors Andrew Boll - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Brooks O'Neil - Lake Street Capital Markets Mayank Mamtani - B. Riley Jim Roumell - Roumell Asset Management Operator Good afternoon, and welcome to Harrow's Second Quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name on exchange on which registered | | --- ...

Harrow Health, Inc. (NASDAQ:HROW) Q1 2023 Earnings Conference Call May 11, 2023 4:45 PM ET Company Participants Jamie Webb - Director, Communications and Investor Relations Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Mayank Mamtani - B. Riley Securities Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon, and welcome to Harrow's First Quarter 2023 Earnings Conference Call. My name is Joe, and I will ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-35814 Harrow Health, Inc. (Exact name of registrant as specified in its charter) Delaware 45-0567010 (State or othe ...

Harrow Health, Inc. (NASDAQ:HROW) Q4 2022 Earnings Conference Call March 23, 2023 4:45 PM ET Company Participants Jamie Webb - Director, Communications and IR Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Sahil Kazmi - B. Riley Securities Operator Good afternoon. And welcome to Harrow’s Q4 2022 Earnings Conference Call. My name is MJ, and I will be your operator for today’s call. At this time, all participan ...

Financial Performance - Total revenues for the year ended December 31, 2022, were $88,595,000, an increase of $16,119,000 (22.2%) compared to $72,476,000 in 2021[271]. - Product sales, net for 2022 were $83,524,000, up from $69,104,000 in 2021, reflecting an increase of $14,420,000 (20.9%) due to higher sales volumes of ophthalmology products[271]. - Gross profit for 2022 was $63,212,000, with a gross margin of 71.3%, down from 74.9% in 2021, primarily due to amortization of acquired NDAs and increased production costs[274][275]. - Selling, general and administrative expenses rose to $58,243,000 in 2022, an increase of $16,928,000 (41.0%) from $41,315,000 in 2021, driven by higher consulting and personnel costs[277]. - Research and development expenses decreased to $11,084,000 in 2022 from $3,050,000 in 2021, primarily due to a one-time payment for acquired R&D in 2021[279]. - The net loss for the year ended December 31, 2022, was $14,086,000, compared to a net loss of $18,479,000 for 2021, resulting in a net loss per share of $0.51 for 2022 versus $0.69 for 2021[288]. Cash Flow and Liquidity - Cash on hand at December 31, 2022, was $96,270,000, significantly up from $42,167,000 at the end of 2021, reflecting an increase in liquidity[289]. - Net cash provided by operating activities decreased to $1,705,000 in 2022 from $5,082,000 in 2021, primarily due to increased operating expenses related to product launches[293]. - Net cash used in investing activities was $(1,743,000) in 2022, a decrease from $(18,686,000) in 2021, mainly due to equipment purchases and the sale of non-ophthalmic assets[294]. - Net cash provided by financing activities increased to $54,141,000 in 2022 from $51,470,000 in 2021, primarily from proceeds of $35,000,000 from notes and common stock sales[295]. Acquisitions and Divestitures - The company completed the acquisition of five ophthalmic products (Fab 5 Products) from Novartis for a total of $130,000,000, with an additional milestone payment of up to $45,000,000[264]. - The company divested its non-ophthalmic assets for $6,000,000 in cash, with potential additional payments of up to $4,500,000 based on revenue milestones in 2023[262]. Debt and Interest - Interest expense increased to $7,244,000 in 2022 from $5,436,000 in 2021, attributed to a higher principal balance of loans[281]. - The company secured a loan facility of up to $100,000,000 with a maturity date of December 14, 2025, at an interest rate of 10.875% to finance the Fab 5 Acquisition[268]. Strategic Plans and Future Outlook - The company expects to launch IHEEZO in 2023, supported by increased expenses related to new hires in sales and marketing[277]. - The company plans to use its cash position and generated funds to develop and commercialize FDA-approved products and pursue strategic acquisitions[291]. Investment Losses and Equity - Aggregate losses incurred since inception through December 31, 2022, totaled $109,493,000, mainly due to selling, general and administrative expenses, and research and development costs[289]. - A gain of $5,259,000 was recorded from the sale of non-ophthalmology assets in 2022[286]. - The company recorded a loss of $11,133,000 for its share of losses from unconsolidated entities in 2022, compared to $5,334,000 in 2021[282]. - The company may consider selling ownership interests in Eton, Surface, Melt, or other subsidiaries to sustain operations and capital expenditures[290]. - As of December 31, 2022, the fair market value of Eton Pharmaceuticals, Inc. common stock was $5,589,000, down from $8,503,000 in 2021, reflecting an investment loss of $2,914,000 in 2022 and $10,126,000 in 2021[307]. - The company owns 3,500,000 shares of Surface Ophthalmics, Inc., representing approximately 20% of equity and voting interests, with a recorded equity in net loss of $1,314,000 for the year ended December 31, 2021[308]. - The investment in Melt Pharmaceuticals, Inc. was recorded at $0 as of December 31, 2022, with equity in net losses of $11,133,000 in 2021 and $4,020,000 in 2022[312][313]. - Melt Pharmaceuticals, Inc. raised approximately $11,400,000 in its Series A Preferred Stock Agreement, resulting in a gain of $5,810,000 at the time of deconsolidation[310][311]. Research and Development - Stock-based compensation is recognized based on estimated fair values using the Black-Scholes option pricing model and Monte-Carlo simulation model[315]. - Research and development expenses include costs related to clinical trials and contract services, with all costs expensed as incurred[318]. - Upfront and milestone payments for technology acquisition and licensing are expensed as R&D in the period incurred[319]. Other Financial Information - The company has not engaged in any off-balance sheet arrangements, except for standard operating leases[326]. - There were no unrecognized tax benefits affecting the effective tax rate as of December 31, 2022 and 2021[317]. - The company reviews goodwill and indefinite-lived intangible assets for impairment annually, with a two-step process for testing[323][324].

Letter to Stockholders November 14, 2022 Dear Harrow Stockholders: I am pleased to report third quarter results that included 22% year-over-year revenue growth and the company remaining "in the black" while we prepare to launch IHEEZO™, generate new high-value revenues from our portfolio of FDA-approved branded pharmaceutical products (BPPs), and advance our market-leading ImprimisRx compounded pharmaceuticals products (CPPs) brand. Here are a few recent noteworthy events connected to the continued executio ...

Harrow Health, Inc. (NASDAQ:HROW) Q3 2022 Earnings Conference Call November 14, 2022 4:45 PM ET Company Participants Jamie Webb – Director-Communications and Investor Relations Mark L. Baum – Chief Executive Officer Andrew Boll – Chief Financial Officer Conference Call Participants Jeffrey Cohen – Ladenburg Thalmann Sahil Kazmi – B. Riley Operator Good afternoon, and welcome to Harrow’s Third Quarter 2022 Earnings Conference Call. My name is Andrea, and I’ll be your operator for today’s call. At this time, ...